High blood pressure, oxygen radicals and antioxidants: Etiological relationships

Medical Hypotheses

Volumn 46, Issue 4, 1996, Pages 414-420

  Romero Alvira, D ^a   Roche, E ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALCOHOL; ANTIOXIDANT; FREE RADICAL; OXYGEN RADICAL;

AGING; ANTIOXIDANT ACTIVITY; HUMAN; HYPERTENSION; HYPOTHESIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0029965875     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90196-6     Document Type: Article

References (76)

1. Williams G H. Hypertensive vascular disease. In: Wilson J D, Braunwald E, Isselbacher K J et al, eds. Principles of Internal Medicine. 12th edn. New York: McGraw-Hill, 1991: 1001-1015.
2. Amery A, Bixko P, Clement D et al. Mortality and morbidity results for the European working party on high blood pressure in elderly trial. Lancet 1985; 1: 1349-1354.
3. Oberman A, Wassetheil-Smoller S, Langford HG et al. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med 1990; 112: 89-95.
4. Ames B N, Shigenaga M K, Hagen T M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-7922.
5. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon, 1989.
6. Cadenas E. Biochemistry of oxygen toxicity. Annu Rev Biochem 1989; 58: 79-110.
7. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362: 709-715.
8. Stadtman E R. Oxidation of free amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 1993; 62: 797-821.
9. Freeman B A, Crapo J D. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47: 412-426.
10. Cerutti P A. Prooxidant states and tumor promotion. Science 1985; 227: 375-381.
11. Frohilich E D, Messerli F H, Reisin E, Dünn FG. The problems of obesity and hypertension. Hypertension 1983; 5: 71-78.
12. Dustan H P. Atherosclerosis complicating chronic hypertension: George Lyman Duff Lecture. Circulation 1974; 50: 871-879.
13. Tauber A I, Baboir B M. Evidence of hydroxyl radical generation by human neutrophils. J Clin Invest 1977; 60: 374-379.
14. Weiss S J, King G W, LoBuglio A F. Evidence of hydroxyl radical generation by human monocytes. J Clin Invest 1977; 60: 370-373.
15. Biemond P, van Eijk H G, Swaack A J, Koster J F. Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes: possible mechanism in inflammation diseases. J Clin Invest 1984; 73: 1576-1579.
16. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
17. Krolewski A S, Canessa M, Warram J H et al. Predisposition to hypertension and susceptibility to renal disease insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 140-145.
18. Christophersen B O. Reduction of X-ray-induced DNA and thymine hydroperoxides by rat liver glutathione peroxidase. Biochim Biophys Acta 1969; 186: 387-389.
19. Thomas H F, Herriot R M, Hahn B S, Wang S V. Thymine hydroperoxide as a mediator in ionising radiation mutagenesis. Nature 1976; 259: 341-343.
20. Little C, O'Brien P J. An intracellular GSH-peroxidase with a lipid peroxide substrate. Biochem Biophys Res Commun 1968; 31: 145-150.
21. Flohé L, Zimmermann R. The role of GSH peroxidase in protecting the membrane of rat liver mitochondria. Biochim Biophys Acta 1970; 223: 210-213.
22. Rush G T, Hook J B. The kidney as a target organ for toxicity. In: Cohen G M, ed. Target Organ Toxicity. Boca Raton, FL: CRC Press, 1988: 1-18.
23. Goyer R A. Cadmium nephropathy. In: Porter G A, ed. Nephrotoxic Mechanism of Drugs and Environmental Toxins. New York: Plenum Press, 1982.
24. Hathcock J N, Rader J I. Food additives, contaminants, and natural toxins. In: Shils M E, Ison J A, Shike M, eds. Modern Nutrition in Health and Disease, 8th edn. Philadelphia, PA: Lea and Febiger, 1994.
25. Malhotra H, Mathur D, Mehta S R, Khandelwal P D. Pressor effects of alcohol in normotensive and hypertensive subjects. Lancet 1985; 2: 584-586.
26. Cederbaum A I, Dicker E, Rubin E, Cohen G. The effect of dimethylsulfoxide and other hydroxyl-radicals scavengers on the oxidation of ethanol by rat liver microsomes. Biochem Biophys Res Commun 1977; 78: 1254-1262.
27. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 1975: 2994-2998.
28. Litov R E, Irving D H, Downey J E, Tappel A L. Lipid peroxidation: a mechanism involved in acute ethanol toxicity as demonstrated by in vivo pentane production in the rat. Lipids 1978; 13: 305-307.
29. Hochstein P, Jain S K. Association of lipid peroxidation and polymerization of membrane proteins with erythrocyte aging. Fed Proc 1981; 40: 183-188.
30. Davis J F, Felder M R. Mouse ethanol-inducible cytochrome P-450 (P450IIE1). Characterization of cDNA clones and testosterone induction in kidney tissue. J Biol Chem 1993; 268: 16584-16589.
31. Kharbanda S, Nakamura T, Kufe D. Induction of the c-jun proto-oncogene by a protein kinase C-dependent mechanism during exposure of human epidermal keratinocytes to ethanol. Biochem Pharmacol 1993; 45: 675-681.
32. Shamberger R J, Andreone T L, Willis C E. Antioxidants and cancer. IV. Initiating activity of malonaldehyde as a carcinogen. J Natl Cancer Inst 1974; 53: 1771-1773.
33. Troll W, Belman S, Goldstein B D, Mukai F, Machlin L. Effect of feeding unsaturated or saturated fat on carcinogenesis on mouse skin. Cancer Res 1978; 19: 106.
34. Willet W C, Reynolds R D, Cottrel-Hoehner S, Sampson L, Brown M L. Validation of a semi-quantitative food frequency questionnaire: comparison with a one-year diet record. J Am Diet Assoc 1987; 87: 43-47.
35. Franceschi C, Crepaldi G, Cristofalo V J, Vijg J, eds. Aging and cellular defense mechanisms. Ann N Y Acad Sci, vol. 663, New York, 1992.
36. Gilliland B C. Systemic sclerosis (scleroderma). In: Wilson J D, Braunwald E, Isselbacher K J et al, eds. Principles of Internal Medicine. 12th edn. New York: McGraw-Hill, 1991: 1443-1448.
37. Sharp G C. Mixed connective tissue disease. In: Wilson J D, Braunwald E, Isselbacher K J et al, eds. Principles of Internal Medicine. 12th edn. New York: McGraw-Hill, 1991.
38. Jaffe J H, Martin W R. Opioid analgesics and antagonists. In: Gilman A G, Rail T W, Nies A S, Taylor P, eds. The Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon Press, 1990.
39. Tabuenca J M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981; 2: 567-568.
40. Vuorio E, de Crombrugghe B. The family of collagen genes. Annu Rev Biochem 1990; 59: 837-872.
41. Przyklenk K, Kloner R A. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991; 121: 1319-1330.
42. Palier M S, Manivel J C. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992; 42: 1345-1354.
43. Baum B J, Moss J, Breul S D, Crystal R G. Association in normal human fibroblasts of elevated levels of adenosine 3′:5′ monophosphate with a selective decrease in collagen production. J Biol Chem 1978; 253: 3391-3394.
44. Baum B J, Moss J, Breul S D, Berg R A, Crystal R G. Effect of cyclic AMP on the intracellular degradation of newly synthesized collagen. J Biol Chem 1980; 255: 2843-2847.
45. Ruwart M J, Rush B D, Snyder K F, Peters K M, Appelman H D, Henley K S. 16,16 dimethyl prostaglandin E2 delays collagen formation in nutritional injury in rat liver. Hepatology 1988; 8: 61-64.
46. Harper E. Collagenases. Annu Rev Biochem 1980; 49: 1063-1078.
47. Richards C D, Raferty J A, Reynolds J J, Saklatvala J. Porcine collagenase from sinovial fibroblast cDNA sequence and modulation of expression of RNA in vitro by various cytokines. Matrix 1991; 11: 161-167.
48. Rogart R. Sodium channels in nerve and muscle membrane. Annu Rev Physiol 1981; 43: 711-725.
49. Carafoli E, Scarpa A, eds. Transport ATPases. Ann N York Acad Sci, vol. 402, New York, 1982.
50. + dans l'hypertension essentielle. Variations physiologiques et pharmacologiques. Arch Mal Coeur 1984; 77: 1283-1287.
51. Lindner A, Kenny M, Meacham A J. Effects of a circulating factor in patients with essential hypertension on intracellular free calcium in normal platelets. N Engl J Med 1987; 316: 509-513.
52. Helwing H P, Hochrein H, Hennersdorsf G. Zur Wirkung von Vitamin E bei Digitalisintoxikation. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 1969; 236: 220-221.
53. Hochrein H, Helwing HP. Klinische und experimentelle Befunde über einen kardialen Vitamin E-Effekt. In: Von Kress H, ed. Klinische und physiologisch-chemische Probleme. Stuttgart: Blum, 1969: 337-352.
54. Helwing HP, Hochrein H, Helwing B. Vitamine E in der Behandlung der Digitalisintoxikation. Arzneim Forsch 1971; 21: 335-342.
55. Mitchell J R, Nelson S D, Thorgeirsson S S, McMurty R J, Dybing E. Metabolic activation: biochemical basis for many drug-induced liver injuries. In: Popper H, Schaffner F, eds. Progress in Liver Diseases, vol. 5. New York: Grune and Stratton, 1976: 259-279.
56. 10 as an antioxidant of lipid peroxidation in bovine heart mitochondria. In: Yamanura Y, Folkers K, Ito Y, eds. Biochemical and Clinical Aspects of Coenzyme Q, vol. 2. Amsterdam: Elsevier North Holland Biomedical Press, 1980: 15-26.
57. 10. Experentia 1980; 36: 1002-1003.
58. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?. Circulation 1988; 77: I-30-I-39.
59. Frohlich E D. Potential mechanism explaining the risk of left ventricular hypertrophy. Am J Cardiol 1987; 59: 91A-97A.
60. Messerli F H, Ventura H O, Elizardi D J, Dunn F G, Frohlich E D. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
61. Vatner S F. Reduced subendocardial coronary perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988; 62: 94E-98E.
62. Vrobel T R, Ring W S, Anderson R W, Emery R W, Bache R J. Effect of heart rate on myocardial blood flow in dogs with left ventricular hypertrophy. Am J Physiol 1980; 239: H621-H627.
63. Alyono D, Anderson R W, Parrish D C, Dai X-Z, Bache R J. Alterations of myocardial blood flow associated with experimental canine left ventricular hypertrophy secondary to valvular aortic stenosis. Cir Res 1986; 58: 47-57.
64. Fujii A M, Gelpi R, Mirsky I, Vatner S F. Systolic and diastolic dysfunction during atrial pacing in conscious dogs with left ventricular hypertrophy. Cir Res 1988; 62: 462-470.
65. Murray P A, Vatner S F. Abnormal vascular response to exercise in dogs with severe right ventricular hypertrophy. J Clin Invest 1981; 67: 1314-1323.
66. Vatner S F, Murray P A. Changes in autonomic control of peripheral vascular resistance in dogs with severe right ventricular hypertrophy and failure. In: Disturbances of neurogenic control of the circulation. Bethesda MD; Am Physiol Soc, 1981: 51.
67. Bache R J, Dai X-Z, Alyono D, Vrobel T R, Homans D C. Myocardial blood flow during exercise in dogs with left ventricular hypertrophy produced by aortic banding and perinephritic hypertension. Circulation 1987; 76: 835-842.
68. Murray PA, Vatner SF. Reduction of maximal coronary vasodilator capacity in conscious dogs with severe right ventricular hypertrophy. Cir Res 1981; 48: 27-33.
69. Bache R J, Alyono D, Subblet E, Dai X-Z. Myocardial blood flow in left ventricular hypertrophy developing in young and adult dogs. Am J Physiol 1986; 251: H949-H956.
70. Kiowski W, Burkort F. Effect of vasodilators on the coronary circulation in congestive heart failure. Am J Cardiol 1988; 62: 99E-103E.
71. Reams G P, Bauer J H. Long-term effects of enalapril monotherapy and enalapril/hydrochlorothiazide combination therapy on blood pressure, renal function and body fluid composition. J Clin Hypertens 1986; 2: 55-63.
72. Breisch E A, Bove A A, Phillips S J. Myocardial morphometrics in pressure overload left ventricular hypertrophy and regression. Cardiovasc Res 1980; 14: 161-168.
73. Cutilleta A F, Dowell R T, Rudnik M, Arcilla R A, Zak R. Regression in myocardial hypertrophy. I. Experimental model, changes in heart weight, nucleic acid and collagen. J Mol Cell Cardiol 1975; 7: 767-780.
74. Cooper G, Satava R M, Harrison C E, Coleman H N. Normal myocardial function and energetics after reversing pressure overload hypertrophy. Am J Physiol 1974; 226: 1158-1165.
75. Cruickshank JM, Thorp JM, Zacharias F J. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-584.
76. Willett W C. Diet and health: what should we eat? Science 1994; 264: 532-537.